【摘要】 目的:评价国产异长春花碱(艾克宁)与顺铂(DDP)联合治疗老年(大于65岁)晚期非小细胞肺癌(NSCLC)患者的疗效与安全性。方法:艾克宁25mg/m2静脉注入第1、第8天,顺铂30mg/m2静脉滴注第1天～第3天,每3周～4周为1周期,治疗晚期NSCLC患者63例,A组(>65岁)33例;B组(<65岁)30例。结果:A、B两组有效率分别为45.5%(15/33)、46.7%(14/30),无显著性差异(P>0.05),主要毒性为骨髓抑制、白细胞减少Ⅲ～Ⅳ度发生率A、B两组分别为54.5%(18/33)、46.7%(14/30),无显著性差异(P>0.05),胃肠道反应发生率A、B两组分别为54.5%(18/33)、60.0%(18/30),无显著性差异(P>0.05)。结论:艾克宁与DDP联合治疗老年晚期非小细胞肺癌患者,与非老年患者有同样好的疗效与安全性。更多还原

【Abstract】 OBJECTIVE: To evaluate the efficacy and safety of vinorelbine (VRB) in combination with cisplatin (DDP) in the treatment of elderly patients (aged over 65 years) with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 63 patients with advanced NSCLC were enrolled: 33 aged over 65 years were assigned to group A, and 30 aged less than 65 years were assigned to group B. The patients were administered with NVB 25 mg/m~2 iv gtt on days 1 and 8 plus DDP 30 mg/m~2 iv gtt from the first day to the third day, with 3～4 weeks as 1 cycle of therapy. RESULTS: The responsive rates of group A and B were 45.5% (15/33) and 46.7% (14/30), respectively, and no significant difference were noted between the two groups (P>0.05). Myelosuppression was the chief toxic reactions; incidences of Grade Ⅲ～Ⅳ leucopenia in group A and B were 54.5%(18/33) and 46.7%(14/30), respectively, and there was no significant differences between the two groups (P>0.05), and incidences of gastrointestinal tracts in group A and B were 54.5%(18/33) and 60.0%(18/30) respectively, and there was no significant difference between the two groups (P>0.05). CONCLUSION: NVB and DDP used concomitantly showed a same satisfactory efficacy and safety in elderly (>65 years) patients with advanced NSCLC as in those less than 65 years with advanced NSCLC.更多还原